J. Bradley White

Popular Topics

Food, Drugs, Healthcare, Life Sciences

DETAILS

Canada

+1 416 3622111

AUTHORS CONTENT

The Impact Of Stronger Drug Dosing Patents On Canadian Drug Access

Canada Healthcare

U.K. Appellate Court Rules Artificial Neural Network Application Is Not Patent-Eligible Subject Matter

Canadian Intellectual Property Office (CIPO) Increasing Official Fees Effective January 1, 2024

Canadian Court Again Rejects Problem-solution Approach To Subject-matter Eligibility Of Computer-implemented Patents

Act Now: Request Examination Early To Avoid Excess Claims Fees And Other Restrictions Under Proposed New Canadian Patent Rules

Canadian Courts Are Interpreting Supplementary Pharmaceutical Patent Protection More Broadly Than Their EU Counterparts

Choueifaty Patent Application Found To Possess Patentable Subject-matter

Canadian Patent Office Issues Guidance On Computer-implemented And Medical Inventions Following Choueifaty Decision

Federal Court Invalidates Tadalafil Dosage Patent Finding Dose Selection To Be Routine

Intellectual Property Litigation In The Federal Court

Canada Litigation

Canadian Intellectual Property Office (CIPO) Deadline Extension

Canadian Court Interprets CETA Drug Patent Extensions More Broadly Than EU Equivalent

Change Is Coming With New Canadian Patent Rules/Amended Patent Act

Canada Takes Major Steps Toward Enhanced Biosimilar Access

Canada Healthcare

Canada's Patent Linkage Regulations Get Long-Awaited Makeover

Supreme Court Holds That Promises Are Not The Yardstick To Measure Patent Utility In Canada

Federal Court Of Appeal Provides Much-Needed Clarity On The "Obvious To Try" Test And Meaning Of "Inventive Concept"

Industrial Design Protection Becomes More Animated And Colourful In Canada

Privilege For Patent And Trademark Agents Now In Force In Canada

$125-Million Pharmaceutical Damages Award Undone By Hearsay Rule

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More